Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plcFORM 8.5 (EPT/RI)
- IFFIFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian ConsumersCompanies: International Flavors & FragrancesNEW DELHI, August 25, 2026--IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook.
- SkyDrive Inc.SkyDrive to Evaluate Potential Routes for eVTOL Medical Logistics in India in Partnership with Air India and SuzukiTOYOTA, Japan, August 25, 2026--SkyDrive Inc. ("SkyDrive"), a leading Japanese developer, manufacturer, and seller of compact eVTOL aircraft (*1), today announced that it will move forward with evaluating initial operational routes for the introduction of eVTOL medical logistics services in India, in partnership with Air India and Suzuki. This is part of the Memorandum of Understanding (MoU) that the three organizations signed in July 2026 to jointly study the feasibility of such operations.(*2)
- Nissin Foods Announces 2026 Interim ResultsFinancial Highlights For the six months Ended 30 June 2026 (HK$ million) 2026 2025 Change Revenue 2,071.0 2,014.2 +2.8% Gross Profit 731.0 677.0 +8.0% Gross Profit margin 35.3% 33.6% +1.7pp Profit attributable to owners of the Company 175.2 157.0 +11.6% Net profit margin 8.5% 7.8% +0.7pp Adjusted EBITDA 330.8 303.2 +9.1% Earnings per share (HK cents) 16.79 15.05 +11.6% HONG KONG, August 25, 2026 - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) has announced its interim results for the six months ended 30 June 2026 (“the reporting period”). During the reporting period, the Group delivered solid profit growth, primarily driven by the resilient performance of its instant noodle business. Revenue increased by 2.8% year-on-year from HK$2,014.2 million in 2025 to HK$2,071.0 million in 2026, reflecting continued momentum in its core instant noodle business and broader store coverage in the Chinese Mainland. Gross profit increased by 8.0% year-on-year from HK$677.0 million to HK$731.0 million. Gross profit margin improved by 1.7 percentage points from 33.6% year-on-year to 35.3%, driven primarily by the continued expansion of the higher-margin core instant noodle business, the effective execution of raw material procurement strategies which helped mitigate the impact of raw material price volatility, and improved production efficiency. Profit attributable to owners of the Company increased by 11.6% from HK$157.0 million in 2025 to HK$175.2 million in 2026, representing a net profit margin of 8.5% for the period. The Group’s basic earnings per share increased from 15.05 HK cents to 16.79 HK cents for the period. Adjusted EBITDA increased by 9.1% from HK$303.2 million to HK$330.8 million, representing the Adjusted EBITDA margin of 16.0% for the period, reflecting improved profitability at the operating level. Review and Prospects of Different Business Regions During the reporting period, revenue from the Hong Kong and other regions operations remained stable, increasing by 0.2% to HK$793.5 million (2025: HK$792.3 million), mainly attributable to the continued steady performance of the instant noodle business in the Hong Kong market and increased demand in other regions. Revenue from Chinese Mainland operations increased by 4.5% (in local currency: -0.1%) to HK$1,277.5 million (2025: HK$1,221.9 million), mainly attributable to the increased sales volume of instant noodles and the positive impact of foreign currency translation. In Hong Kong, the instant noodles business delivered steady growth, driven by the resilient performance of flagship brands including Demae Iccho, Hokkaido Iccho, Cup Noodles and Cup Noodles BIG. To further enrich its instant noodle portfolio, the Group introduced a range of new SKUs, such as Nissin Stir Cup Noodles Seafood Flavour Instant Noodle and Nissin Viet Signature Beef Flavour Pho Noodle, and Demae Iccho Scallop and Salt Soup Flavour Instant Noodle. Continuing its IP promotion strategy, the collaboration with Japanese virtual singer “Hatsune Miku” also enhanced brand awareness and strengthened engagement with younger consumers. As for non-noodle business, the Group expanded its premium frozen food portfolio with the launch of the “Doll Dim Sum” series. The Group also introduced a series of limited-edition products to capture seasonal demand and drive sales. Meanwhile, health-focused products, including the Hong Kong-made Nissin Granola and fresh-cut vegetable, continued to gain popularity, reflecting the Company’s commitment to health and wellness. In May 2026, the Group entered into a strategic partnership with Itochu Hong Kong Limited through a joint investment in Nissin Marketing and Sales (H.K.) Limited, which is expected to support the long-term development and competitiveness of the distribution business in Hong Kong and the Chinese Mainland. In other regions, the Company continued to strengthen its presence in Vietnam with a focus on the youth segment to support instant noodles brand growth and market penetration. In Korea, Gaemi Food’s business performance was stable during the period, with the strategic focus on the expansion of its e-commerce business, enhancement of consumer engagement through “KEMY Mall”, and continuous product innovation. Gaemi Food continued to expand its presence in overseas markets including Hong Kong, Vietnam, and Taiwan. In Australia, ABC Pastry recorded stable performance supported by the launch of a range of new premium products. Australia Nissin also maintained solid business momentum during the period, driven by increased sales of instant noodles across nationwide supermarket chains and Asian supermarket channels through ongoing market development efforts and product innovation. In the Chinese Mainland, the Group continued to advance its premiumisation strategy and strengthen its business foundation, while increasing instant noodle sales volume through broader market coverage and more diversified distribution channels. It upgraded select Cup Noodles products by increasing ingredient sizes to deliver an improved tasting experience for consumers. To further enrich its product line-up, the Company also introduced new products such as Nissin U.F.O. Singapore Chilli Crab Flavour, reinforcing its premium and innovative brand positioning. The Company continued its collaboration with the Japanese virtual singer "Hatsune Miku" to raise brand awareness and strengthen connections with consumers. As for the non-noodle business, the Company continued to strengthen its snacks, beverage and frozen food businesses through product innovation to address evolving consumer demand. Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Despite continuing market volatility and geopolitical uncertainties, the Group delivered solid profit growth in the first half of 2026. This was supported by broader market coverage and the resulting increase in sales volume of our flagship brands. These results reflect the resilience of our business model and the effectiveness of our strategic initiatives. Our premiumisation strategy, diversified product portfolio and disciplined cost management have further strengthened our capability to navigate changing market conditions. As we continue to expand our presence in Hong Kong, the Chinese Mainland and overseas markets, we remain focused on delivering quality products and strengthening our brands. We are committed to achieving sustainable long-term growth and creating value for our shareholders.” About Nissin Foods Company Limited Nissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL (公仔)” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets. Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk.
- Edelson Lechtzin LLPSurgeons Choice Medical Center Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal InformationNational class action firm offering free case evaluations to individuals impacted by the Surgeons Choice Medical Center cybersecurity incident — Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims...
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion StageNanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that Opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), has completed its safety run‑in assessment and advanced to the expansion phase based on encouraging efficacy signals and a favorable safety profile.
- Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq RulesAutonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the “July 2026 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75. The resale of the shares of common stock issuable upon exercise of the July 2026 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-297760). The gross proceeds from the exercise of the warrants are expected to be approximately $4.9 million, prior to deducting financial advisory fees and estimated offering expenses.
- Antengene Corporation LimitedAntengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune DiseasesAntengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- Apptly Health Technologies Corp.Apptly Announces $1,000,000 Non-Brokered Private PlacementApptly Health Technologies Corp. (CSE: APPT) (FSE: 4KL) (the "Company") is pleased to announce that it intends to complete a non-brokered private placement of up to 8,000,000 units of the Company (the "Units"), at a price of $0.125 per Unit, for aggregate gross proceeds of up to $1,000,000 (the "Offering"). The Company reserves the right to increase the size of the Offering in its sole discretion. The Offering is not subject to a...
- Astellas Pharma Inc.Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma- ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets - TOKYO, Aug. 24, 2026 -- Astellas Pharma Inc. (TSE: 4503,...
- Johnson & JohnsonFDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsCompanies: Johnson & JohnsonIMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood...
- BetterLife Pharma Inc.BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsBetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta...